个体和综合研究终点：去芜存菁。
Individual and composite study endpoints: separating the wheat from the chaff.
机构信息
Department of Quantitative Health Sciences, University of Massachusetts Medical School, Worcester, Mass; Meyers Primary Care Institute, Worcester, Mass.
Department of Medicine, University of Massachusetts Medical School, Worcester, Mass.
出版信息
Am J Med. 2014 May;127(5):379-84. doi: 10.1016/j.amjmed.2014.01.011. Epub 2014 Jan 28.
Abstract
We provide an overview of the individual and combined clinical endpoints and patient-reported outcomes typically used in clinical trials and prospective epidemiological investigations. We discuss the strengths and limitations associated with the utilization of aggregated study endpoints and surrogate measures of important clinical endpoints and patient-centered outcomes. We hope that the points raised in this overview will lead to the collection of clinically rich, relevant, measurable, and cost-efficient study outcomes.
摘要
我们提供了一个临床终点和患者报告结果的概述，这些终点和结果通常用于临床试验和前瞻性流行病学研究。我们讨论了利用聚合研究终点和重要临床终点和以患者为中心的结果的替代指标的优势和局限性。我们希望在这个概述中提出的观点将导致收集临床丰富、相关、可衡量和具有成本效益的研究结果。
相似文献
1
Individual and composite study endpoints: separating the wheat from the chaff.个体和综合研究终点：去芜存菁。
Am J Med. 2014 May;127(5):379-84. doi: 10.1016/j.amjmed.2014.01.011. Epub 2014 Jan 28.
2
Outcomes and endpoints in trials of cancer treatment: the past, present, and future.癌症治疗试验中的结局和终点：过去、现在和未来。
Lancet Oncol. 2015 Jan;16(1):e32-42. doi: 10.1016/S1470-2045(14)70375-4. Epub 2014 Dec 29.
3
Biomarkers and surrogate endpoints in clinical trials.生物标志物和临床试验中的替代终点。
Stat Med. 2012 Nov 10;31(25):2973-84. doi: 10.1002/sim.5403. Epub 2012 Jun 18.
4
Post hoc analyses: after the facts.事后分析：在事实发生之后。
Transplantation. 2015 Jan;99(1):17-20. doi: 10.1097/TP.0000000000000581.
5
Reducing unnecessary measurements in clinical trials with multiple primary endpoints.减少具有多个主要终点的临床试验中的不必要测量。
J Biopharm Stat. 2016;26(4):631-43. doi: 10.1080/10543406.2015.1052497. Epub 2015 Jun 22.
6
Small trials focusing on surrogate end points may be uninformative.专注于替代终点的小型试验可能无法提供有用信息。
Eur J Appl Physiol. 2007 Apr;99(6):707-8. doi: 10.1007/s00421-006-0387-2. Epub 2007 Jan 12.
7
The Inclusion of Economic Endpoints as Outcomes in Clinical Trials Reported to ClinicalTrials.gov.ClinicalTrials.gov 报告的临床试验中纳入经济学结局作为结局指标。
J Manag Care Spec Pharm. 2020 Apr;26(4):386-393. doi: 10.18553/jmcp.2020.26.4.386.
8
Surrogate endpoints for overall survival in digestive oncology trials: which candidates? A questionnaires survey among clinicians and methodologists.消化系统肿瘤临床试验中总生存的替代终点：哪些候选物？临床医生和方法学家问卷调查。
BMC Cancer. 2010 Jun 10;10:277. doi: 10.1186/1471-2407-10-277.
9
Endpoints in respiratory diseases.呼吸疾病的终点。
Eur J Clin Pharmacol. 2011 May;67 Suppl 1:49-59. doi: 10.1007/s00228-010-0922-2. Epub 2010 Nov 23.
10
Endpoint selection for noninferiority percutaneous coronary intervention trials: a methodological description.非劣效性经皮冠状动脉介入试验的终点选择：方法学描述
Ther Adv Cardiovasc Dis. 2020 Jan-Dec;14:1753944720911329. doi: 10.1177/1753944720911329.
引用本文的文献
1
How to Survive and Succeed in the Design and Execution of a Collaborative Randomized Controlled Trial.如何在协作性随机对照试验的设计与实施中生存并取得成功。
United European Gastroenterol J. 2025 Jul;13(6):911-916. doi: 10.1002/ueg2.12726. Epub 2025 Apr 27.
2
A Bayesian method for adverse effects estimation in observational studies with truncation by death.一种用于在存在死亡截断的观察性研究中估计不良事件的贝叶斯方法。
Stat Methods Med Res. 2024 Nov;33(11-12):2079-2097. doi: 10.1177/09622802241283170. Epub 2024 Nov 5.
3
Conflicts of interest in clinical practice: lessons learned from cardiovascular medicine.临床实践中的利益冲突：心血管医学的经验教训。
Eur J Cardiothorac Surg. 2024 Sep 2;66(3). doi: 10.1093/ejcts/ezae296.
4
Time Gained to Cardiovascular Disease by Intensive Lipid-Lowering Therapy: Results of Individual Placebo-Controlled Trials and Pooled Effects.降脂治疗获得的心血管获益时间：来自个体化安慰剂对照试验和汇总效应的结果。
Am J Cardiovasc Drugs. 2024 Nov;24(6):743-752. doi: 10.1007/s40256-024-00668-y. Epub 2024 Aug 14.
5
Development and internal validation of machine learning-based models and external validation of existing risk scores for outcome prediction in patients with ischaemic stroke.基于机器学习的模型的开发与内部验证以及现有风险评分在缺血性中风患者预后预测中的外部验证
Eur Heart J Digit Health. 2023 Nov 22;5(2):109-122. doi: 10.1093/ehjdh/ztad073. eCollection 2024 Mar.
6
Association of Periodic Limb Movements and Obstructive Sleep Apnea With Risk of Cardiovascular Disease and Mortality.周期性肢体运动和阻塞性睡眠呼吸暂停与心血管疾病风险及死亡率的关联。
J Am Heart Assoc. 2024 Feb 6;13(3):e031630. doi: 10.1161/JAHA.123.031630. Epub 2024 Jan 19.
7
Underrepresentation of women in randomized controlled trials: a systematic review and meta-analysis.女性在随机对照试验中的代表性不足：系统评价和荟萃分析。
Trials. 2022 Dec 21;23(1):1038. doi: 10.1186/s13063-022-07004-2.
8
Coronary CT angiography and serum biomarkers are potential biomarkers for predicting MACE at three-months and one-year follow-up.冠状动脉 CT 血管造影和血清生物标志物是预测三个月和一年随访时 MACE 的潜在生物标志物。
Int J Cardiovasc Imaging. 2022 Dec;38(12):2763-2770. doi: 10.1007/s10554-022-02646-4. Epub 2022 Aug 8.
9
Breaking new frontiers: Assessment and re-evaluation of clinical trial design for nutraceuticals.开拓新领域：营养保健品临床试验设计的评估与重新评估
Front Nutr. 2022 Sep 23;9:958753. doi: 10.3389/fnut.2022.958753. eCollection 2022.
10
Composite outcomes in observational studies of Crohn's disease: a systematic review and meta-analysis.克罗恩病观察性研究中的复合结局：一项系统评价与荟萃分析
Therap Adv Gastroenterol. 2022 May 13;15:17562848221092754. doi: 10.1177/17562848221092754. eCollection 2022.
本文引用的文献
1
Surrogate outcomes in clinical trials: a cautionary tale.临床试验中的替代结局：一则警示故事。
JAMA Intern Med. 2013 Apr 22;173(8):611-2. doi: 10.1001/jamainternmed.2013.3037.
2
NIH toolbox for assessment of neurological and behavioral function.NIH 神经行为功能评估工具包。
Neurology. 2013 Mar 12;80(11 Suppl 3):S2-6. doi: 10.1212/WNL.0b013e3182872e5f.
3
Approval of a tuberculosis drug based on a paradoxical surrogate measure.基于矛盾替代指标批准一种结核病药物。
JAMA. 2013 Apr 3;309(13):1349-50. doi: 10.1001/jama.2013.623.
4
Evaluation of early percutaneous coronary intervention vs. standard therapy after fibrinolysis for ST-segment elevation myocardial infarction: contribution of weighting the composite endpoint.评价 ST 段抬高型心肌梗死溶栓后早期经皮冠状动脉介入治疗与标准治疗的效果：复合终点加权的作用。
Eur Heart J. 2013 Mar;34(12):903-8. doi: 10.1093/eurheartj/ehs438. Epub 2012 Dec 19.
5
Universal health outcome measures for older persons with multiple chronic conditions.通用健康结局指标用于评估患有多种慢性病的老年人。
J Am Geriatr Soc. 2012 Dec;60(12):2333-41. doi: 10.1111/j.1532-5415.2012.04240.x. Epub 2012 Nov 29.
6
Clinical trials and tribulations--lessons from pulmonary fibrosis.临床研究的曲折——肺纤维化的启示。
QJM. 2012 Nov;105(11):1043-7. doi: 10.1093/qjmed/hcs066. Epub 2012 May 29.
7
Non-inferiority study design: lessons to be learned from cardiovascular trials.非劣效性研究设计：心血管试验的经验教训。
Eur Heart J. 2012 Jun;33(11):1318-24. doi: 10.1093/eurheartj/ehs099. Epub 2012 May 7.
8
Asthma outcomes: composite scores of asthma control.哮喘结局：哮喘控制的综合评分。
J Allergy Clin Immunol. 2012 Mar;129(3 Suppl):S24-33. doi: 10.1016/j.jaci.2011.12.980.
9
Asthma outcomes workshop: overview.哮喘结局研讨会：概述。
J Allergy Clin Immunol. 2012 Mar;129(3 Suppl):S1-8. doi: 10.1016/j.jaci.2011.12.985.
10
The win ratio: a new approach to the analysis of composite endpoints in clinical trials based on clinical priorities.胜率：一种基于临床重点的临床试验中综合终点分析的新方法。
Eur Heart J. 2012 Jan;33(2):176-82. doi: 10.1093/eurheartj/ehr352. Epub 2011 Sep 6.
Zotero 插件